10.1.4 Gout and cytotoxic-induced hyperuricaemia
10.1.4 Gout and cytotoxic-induced hyperuricaemia
| |
| Acute attacks of gout |
| High doses of NSAIDs are usually used. |
| Colchicine is an alternative. The BNF dose of colchicine is known to cause gastrointestinal side effects, particularly in patients with |
| impaired renal function. Local rheumatologists recommend colchicine be given at a dose of 500micrograms twice daily for acute |
| gout. |
| GREEN Colchicine tablets 500 micrograms |
| |
| Long term control of gout |
| Long term control to reduce formation of uric acid can be achieved with allopurinol. It should not be started during an acute |
| attack. For approximately the first 6 weeks of therapy NSAIDs or colchicine should also be given. |
| GREEN Allopurinol tablets 100mg, 300mg |
| |
| Febuxostat |
| NICE TA164 advises febuxostat, within its marketing authorisation, as an option for the management of chronic hyperuricaemia in |
| gout only for people who are intolerant of allopurinol or for whom allopurinol is contraindicated. Intolerance of allopurinol is |
| defined as adverse effects that are sufficiently severe to warrant its discontinuation, or to prevent full dose escalation for optimal |
| effectiveness as appropriate within its marketing authorisation. Annual treatment costs for febuxostat are approximately £318 |
| while for allopurinol they are approximately £16. |
| |
| Drug Safety Update July 2019 advises avoiding treatment with febuxostat in patients with pre-existing major cardiovascular disease |
| (for example, myocardial infarction, stroke or unstable angina), unless no other therapy options are appropriate. |
| |
| AMBER Febuxostat tablets 40mg, 80mg |
| |
| Hyperuricaemia associated with cytotoxic drugs |
| RED Rasburicase 1.5mg (Consultant Haematologist use only) |
| |
| |
| |
